📊 SDGR Key Takeaways
Is Schrodinger, Inc. (SDGR) a Good Investment?
Schrodinger is a cash-burning biotech company with zero revenue growth, deteriorating operational losses reaching -83.3% margin, and negative free cash flow of -$17.3M annually. While the company maintains a fortress balance sheet with $260M cash and no debt, the flat-lined business lacks commercialization traction and shows no clear path to operational profitability.
Schrodinger, Inc. Key Strengths (SDGR)
- Fortress balance sheet with $260.3M cash reserves and zero debt, providing 15-year cash runway
- Healthy gross margins of 50.4% demonstrate viable product economics at the unit level
- Excellent liquidity metrics (2.74x current ratio) ensuring near-term financial flexibility
SDGR Stock Risks: Schrodinger, Inc. Investment Risks
- Negative free cash flow of -$17.3M annually with no improvement trajectory despite substantial cash reserves
- Revenue completely stalled at $58.6M with 0% YoY growth indicating failed commercialization momentum
- Unsustainable cost structure with operating losses of -$48.8M (-83.3% margin) that exceed gross profit generation
Key Metrics to Watch
- Revenue growth acceleration from 0% to establish market traction and product demand
- Operating cash flow inflection from negative to positive demonstrating path to breakeven
- Operating margin improvement toward breakeven as revenue scales or cost structure optimizes
Schrodinger, Inc. (SDGR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.74x current ratio provides a solid financial cushion.
SDGR Profit Margin, ROE & Profitability Analysis
SDGR vs Healthcare Sector: How Schrodinger, Inc. Compares
How Schrodinger, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Schrodinger, Inc. Stock Overvalued? SDGR Valuation Analysis 2026
Based on fundamental analysis, Schrodinger, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Schrodinger, Inc. Balance Sheet: SDGR Debt, Cash & Liquidity
SDGR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Schrodinger, Inc.'s revenue has grown significantly by 137% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.54 reflects profitable operations.
SDGR Revenue Growth, EPS Growth & YoY Performance
SDGR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $58.6M | -$59.8M | $-0.81 |
| Q3 2025 | $35.3M | -$32.8M | $-0.45 |
| Q2 2025 | $47.3M | -$43.2M | $-0.59 |
| Q1 2025 | $36.6M | -$54.7M | $-0.76 |
| Q3 2024 | $35.3M | $4.3M | $-0.52 |
| Q2 2024 | $35.2M | $4.3M | $0.06 |
| Q1 2024 | $36.6M | -$54.7M | $-0.76 |
| Q3 2023 | $37.0M | $4.3M | $-0.56 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Schrodinger, Inc. Dividends, Buybacks & Capital Allocation
SDGR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Schrodinger, Inc. (CIK: 0001490978)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SDGR
What is the AI rating for SDGR?
Schrodinger, Inc. (SDGR) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SDGR's key strengths?
Claude: Fortress balance sheet with $260.3M cash reserves and zero debt, providing 15-year cash runway. Healthy gross margins of 50.4% demonstrate viable product economics at the unit level.
What are the risks of investing in SDGR?
Claude: Negative free cash flow of -$17.3M annually with no improvement trajectory despite substantial cash reserves. Revenue completely stalled at $58.6M with 0% YoY growth indicating failed commercialization momentum.
What is SDGR's revenue and growth?
Schrodinger, Inc. reported revenue of $58.6M.
Does SDGR pay dividends?
Schrodinger, Inc. does not currently pay dividends.
Where can I find SDGR SEC filings?
Official SEC filings for Schrodinger, Inc. (CIK: 0001490978) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SDGR's EPS?
Schrodinger, Inc. has a diluted EPS of $-0.81.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SDGR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Schrodinger, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SDGR stock overvalued or undervalued?
Valuation metrics for SDGR: ROE of -19.1% (sector avg: 15%), net margin of -102.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SDGR's AI grade for 2026?
Our dual AI analysis gives Schrodinger, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SDGR's free cash flow?
Schrodinger, Inc.'s operating cash flow is $-14.8M, with capital expenditures of $2.5M. FCF margin is -29.6%.
How does SDGR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -102.5% (avg: 12%), ROE -19.1% (avg: 15%), current ratio 2.74 (avg: 2).